• 四川大學(xué)華西醫(yī)院感染性疾病中心，四川成都 610041;

目的：對鮑曼不動桿菌感染的臨床特征和耐藥性進行分析，為臨床診治提供參考。方法：對2005年1月～2006年6月我院臨床分離的共107株鮑曼不動桿菌通過瓊脂對倍稀釋法進行MIC測定；同時對相應(yīng)的臨床病例進行回顧性分析。結(jié)果：107株鮑曼不動桿菌大多分離自痰液，主要來自于ICU病房；且91.59%的患者同時存在2種以上基礎(chǔ)疾病。鮑曼不動桿菌對氨曲南耐藥率最高，為89.72%，依次是頭孢西丁(87.85%)，頭孢哌酮(76.64%)、哌拉西林(69.16%)、頭孢噻肟(65.42%)、環(huán)丙沙星(65.42%)、阿米卡星(56.07%)、頭孢他定(5514%)等。結(jié)論：我院鮑曼不動桿菌耐藥情況嚴重，治療首選碳青霉烯類抗生素，其次可選用頭孢吡肟、頭孢哌酮/舒巴坦。

引用本文： 杜蓉,馮萍,陳慧莉,俞汝佳. 107株鮑曼不動桿菌感染臨床資料與耐藥性分析. 華西醫(yī)學(xué), 2009, 24(2): 339-341. doi: 復(fù)制

1. Clinial and Laboratory Standards Institute(CLSI)/NCCLS.Performance Standards for Antimocrobial Susceptibity testing Standards：Fifteenth Informational Supplement[S].2005，M100S15..
2. Ronald N，Jones AB，Helio S.Contemporary in vitro spectrum of activity summary forantimicrobial agents tested against 18 569 strains nonfermentative Gramnegative bacilli isolated in the SENTRY Antimicrobial Surveillance Program(19972001)[J].International J Antimicrob Agents，2003，22：551-6..
3. 陳民均，王輝.中國重癥監(jiān)護病房革蘭陰性菌耐藥性連續(xù)7年監(jiān)測研究[M].中國醫(yī)院內(nèi)病原菌耐藥監(jiān)測網(wǎng)，2003年5月12日..
4. Tao CM，Chen HL，Liu YG，et al.Analisis on antibiotics resistance of nonfermenting gramnegative bacilli isolated from our hospital during 1998 and 2005[J].Chin J Infect Chemothr，2006，6：399-402..
5. DallaCosta LM，Coelho JM，Souza HA，et al.Outbreak of carbapenemresistant Acinetobacter baumannii producing the OXA23 enzyme in Curitiba，Brazil[J].J Clin Microbiol，2003，41：3403-6..
6. Heritier C，Dubouix A，Poirel L，et al.A nosocomial outbreak of Acinetobacter baumannii isolates expressing the carbapenemhydrolysing oxacillinase OXA58[J].J Antimicrob Chemother，2005，55：115-8..
7. Gehrlein M，Leying H，Cullmann W，et al.Imipenem resistance in Acinetobacter baumannii is due to altered penicillinbinding proteins[J].Chemother，1991，37：405-12..
8. Limansky AS，Mussi MA，Viale AM.Loss of a 29kilodalton outer membrane protein in Acinetobacter baumannii is associated with imipenem resistance[J].J Clin Microbiol，2002，40：4776-8..
  1. 1. Clinial and Laboratory Standards Institute(CLSI)/NCCLS.Performance Standards for Antimocrobial Susceptibity testing Standards：Fifteenth Informational Supplement[S].2005，M100S15..
  2. 2. Ronald N，Jones AB，Helio S.Contemporary in vitro spectrum of activity summary forantimicrobial agents tested against 18 569 strains nonfermentative Gramnegative bacilli isolated in the SENTRY Antimicrobial Surveillance Program(19972001)[J].International J Antimicrob Agents，2003，22：551-6..
  3. 3. 陳民均，王輝.中國重癥監(jiān)護病房革蘭陰性菌耐藥性連續(xù)7年監(jiān)測研究[M].中國醫(yī)院內(nèi)病原菌耐藥監(jiān)測網(wǎng)，2003年5月12日..
  4. 4. Tao CM，Chen HL，Liu YG，et al.Analisis on antibiotics resistance of nonfermenting gramnegative bacilli isolated from our hospital during 1998 and 2005[J].Chin J Infect Chemothr，2006，6：399-402..
  5. 5. DallaCosta LM，Coelho JM，Souza HA，et al.Outbreak of carbapenemresistant Acinetobacter baumannii producing the OXA23 enzyme in Curitiba，Brazil[J].J Clin Microbiol，2003，41：3403-6..
  6. 6. Heritier C，Dubouix A，Poirel L，et al.A nosocomial outbreak of Acinetobacter baumannii isolates expressing the carbapenemhydrolysing oxacillinase OXA58[J].J Antimicrob Chemother，2005，55：115-8..
  7. 7. Gehrlein M，Leying H，Cullmann W，et al.Imipenem resistance in Acinetobacter baumannii is due to altered penicillinbinding proteins[J].Chemother，1991，37：405-12..
  8. 8. Limansky AS，Mussi MA，Viale AM.Loss of a 29kilodalton outer membrane protein in Acinetobacter baumannii is associated with imipenem resistance[J].J Clin Microbiol，2002，40：4776-8..